CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is the oncology-focused biopharmaceutical company that resulted from the business combination between TenX Keane Acquisition Corp and Citius Pharmaceuticals' oncology division, with TenX Keane Capital LLC serving as sponsor. TenX Keane Acquisition completed its IPO in 2021, targeting the healthcare and life sciences sector, and subsequently closed its de-SPAC transaction to bring Citius Oncology to market as a standalone public company. The company filed an 8-K with the SEC on May 15, 2026, accession number 0001213900-26-057883, reflecting ongoing public-company reporting obligations in the oncology and specialty pharmaceuticals space. Sign up at SpacDesk for full filing history, sponsor details, and real-time SPAC data on TENK and hundreds of other transactions.